Psyence Group Inc. (PSYGF)
USD 0.3
(0.0%)
USD 0.3
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -0.52 CAD | -661.35% |
| 2023 | -0.07 CAD | -26.95% |
| 2022 | -0.05 CAD | -2888.89% |
| 2021 | -0.00 CAD | 84.21% |
| 2020 | -0.01 CAD | 38.38% |
| 2019 | -0.02 CAD | 53.98% |
| 2018 | -0.04 CAD | 63.45% |
| 2017 | -0.11 CAD | -271.62% |
| 2016 | -0.03 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 FY | - CAD | -661.35% |
| 2024 Q4 | -0.50 CAD | -19330.77% |
| 2024 Q3 | 0.00 CAD | 170.27% |
| 2024 Q2 | -0.00 CAD | 78.98% |
| 2024 Q1 | -0.02 CAD | 45.17% |
| 2023 Q3 | -0.01 CAD | -9.32% |
| 2023 Q4 | -0.03 CAD | -148.84% |
| 2023 Q1 | -0.01 CAD | -10.4% |
| 2023 FY | - CAD | -26.95% |
| 2023 Q2 | -0.01 CAD | 14.49% |
| 2022 FY | - CAD | -2888.89% |
| 2022 Q3 | -0.01 CAD | -12.5% |
| 2022 Q2 | -0.01 CAD | 9.22% |
| 2022 Q1 | -0.01 CAD | 89.93% |
| 2022 Q4 | -0.01 CAD | 13.19% |
| 2021 FY | - CAD | 84.21% |
| 2021 Q4 | -0.14 CAD | -219.63% |
| 2021 Q2 | -0.00 CAD | -109.09% |
| 2021 Q3 | -0.04 CAD | -852.17% |
| 2021 Q1 | -0.00 CAD | 0.0% |
| 2020 FY | - CAD | 38.38% |
| 2019 FY | - CAD | 53.98% |
| 2018 FY | - CAD | 63.45% |
| 2017 FY | - CAD | -271.62% |
| 2016 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AstraZeneca PLC | 3.84 USD | 113.542% |
| Bristol-Myers Squibb Company PFD CONV 2 | 3.88 USD | 113.402% |
| CSPC Pharmaceutical Group Limited | 0.07 USD | 842.857% |
| Clarus Therapeutics Holdings, Inc. | -8.04 USD | 93.532% |
| Novartis AG | 7.63 USD | 106.815% |
| PT Kalbe Farma Tbk. | 0.00 USD | 13433.333% |